AACR Annual Meeting 2024 Press Program

The American Association for Cancer Research (AACR) hosted its 115th Annual Meeting from April 5-10, 2024, at the San Diego Convention Center in San Diego.

To help reporters plan coverage of the meeting, the AACR public relations team prepared the following press program.

PRESS CONFERENCE 1: SUNDAY, APRIL 7, 2024

AACR Annual Meeting Clinical Trials Committee Cochair Shivaani Kummar, MD, Oregon Health & Science University Knight Cancer Institute, moderated the press conference.

The following studies were presented:

Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status

• Presented by Jiafu Ji, MD, PhD, DrPh, Peking University Cancer Hospital & Institute in Beijing

Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate with Clinical Benefit

• Presented by Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center

Accelerated Aging May Increase the Risk of Early-onset Cancers in Younger Generations

• Presented by Ruiyi Tian, MPH, Washington University School of Medicine in St. Louis

Fewer Than Half of Accelerated Approval Drugs Showed Clinical Benefit in Confirmatory Trials After Five Years

• Presented by Edward Cliff, MBBS, MPH, Brigham and Women’s Hospital and Harvard Medical School

PRESS CONFERENCE 2: Monday, April 8, 2024

AACR Annual Meeting Clinical Trials Committee Cochair Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital, moderated the press conference.

The following studies were presented:

Adagrasib Plus Cetuximab May Provide Clinical Benefit in Patients With KRAS^G12C-mutated Colorectal Cancer

• Presented by Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

Next-generation PARP Inhibitor Demonstrates Clinical Benefit in Patients with Homologous Recombination Repair-deficient Breast Cancer

• Presented by Timothy A. Yap, MBBS, PhD, The University of Texas MD Anderson Cancer Center

An Exosome-based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer

• Presented by Ajay Goel, PhD, City of Hope

PRESS CONFERENCE 3: Tuesday, April 9, 2024

Roy S. Herbst, MD, PhD, Yale Cancer Center, moderated the press conference.

The following studies were presented:

Artificial Intelligence Analysis of DNA Fragmentomes and Protein Biomarkers Noninvasively Detects Ovarian Cancer

• Presented by Victor Velculescu, MD, PhD, FAACR, Johns Hopkins Kimmel Cancer Center

AZD1390 With Radiotherapy Shows Manageable Safety Profile and Preliminary Efficacy for Patients with Glioblastoma in Phase I Trial

• Presented by Jonathan T. Yang, MD, PhD of Memorial Sloan Kettering Cancer Center

Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients with Resected Head and Neck Cancers

• Presented by Olivier Lantz, MD, PhD, Institut Curie in Paris.

aDDITIONAL NEWS RELEASES

A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer

• Presented by Charles Link, MD, Lankenau Institute for Medical Research, part of Main Line Health

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Patients with African and European Ancestries

• Presented by Shyh-Han Tan, PhD, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation

Culturally Sensitive Video Targeting Black Men May Help Increase Awareness About Prostate Cancer

• Presented by Mallorie C. Jones, MA, Perelman School of Medicine at the University of Pennsylvania